Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker    Newsletter   Tax Corner NRI Centre Forums E-Mail Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Hindalco 110.10 0.14
Tata Mot 293.00 3.11
Bhel 205.45 1.76
Tata Stl 309.30 11.59
State Ba 2360.10 2.20
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-Piramal Enterprises Limited
Piramal Enterprises Limited
Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:500302NSE:PELBloomberg:PIHC@INReuters:NICH.BO
Market Lot: 1Face Value: 2ISIN Demat: INE140A01024
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals
 
 
Recent Developments
04-DEC-12 Piramal Enterprises` subsidiary Decision Resources Group, one of the world`s leading research and advisory firms focusing on healthcare insights and analysis, announced that it acquired Abacus International, a pioneer in evidence-based global market access solutions for many of the world`s leading healthcare companies. 20-JUL-12 Piramal Healthcare announced that it has received approval from the Drug Controller General of India (DCGI...   More..
Business Profile Future Plans
CEO Talk
Nicholas Piramal is confident that it will survive in the post-2005 era, when product patents become effective as it aims to partner multinational companies.   Vijay Shah
One To One
Recent news
Latest News
Piramal's IndiaREIT invests Rs 2 billion in two domestic funds  -IRIS 02-Apr-13
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)31-Dec-2012(9)31-Mar-2012 (12)31-Mar-2011 (12)
Net sales 10115.5010962.5015853.60
Other Income1481.102547.303797.20
Total Income11596.6013509.8019650.80
Cost of goods sold11273.8010107.0014753.70
OPBDIT322.803402.804897.10
PAT-793.901307.20128969.10
Gross Block---
Equity capital345.10345.10335.80
EPS (Rs.)-7.70574.30
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-44.16 - 63.050.71 - 1.04
Debt / Equity (x)---
Operating margin (% of OI) 2.825.224.9
Net margin (% of OI)-6.8 9.7656.3
Detailed Financials
Income 
Statement 		Balance Sheet Latest 
Quarterly/Halfyearly 		Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Piramal Tower Annexe
Ganpatrao Kadam Marg
Lower Parel
Mumbai
Maharashtra-400 013
PHONE
(022) 3046 7953
FAX
(022) 2490 2363
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Trade On-line | Wealth Tracker | Newsletters | Tax Corner | NRI Centre | Forums | E-mail | Chat | Search in myiris | Advertise
© All rights reserved. IRIS Business Services Limited
Disclaimer